Table 2 Overall survival (OS) and disease-free survival (DFS) according to DEF6/p16 and DEF6/p53 co-expressions
From: DEF6 expression in ovarian carcinoma correlates with poor patient survival
OS (SE) | 95 % CI | Median (SE) (95 % CI) | P-value | DFS (SE) | 95 % CI | Median (SE) (95 % CI) | P-value | |
|---|---|---|---|---|---|---|---|---|
DEF6/p16 co-expression | ||||||||
DEF6-negative/ p16-negative | 75 (11) | 53–98 | 90 (30) 30–149 | 0.027* | 75 (11) | 52–98 | 90 (30) 30–149 | 0.023* |
DEF6-negative/ p16-positive | 54 (16) | 22–86 | 48 (30) 0–107 | 54 (16) | 22–86 | 48 (30) 0–107 | ||
DEF6-postive/ p16-negative | 41 (10) | 22–61 | 27 (10) 6–47 | 39 (9) | 19–58 | 27 (9) 8–45 | ||
DEF6-positive/ p16-positive | 32 (6) | 19–45 | 21 (4) 12–30 | 32 (6) | 19–44 | 19 (3) 12–25 | ||
DEF6/p53 co-expression | ||||||||
DEF6-negative /p53 (scores 1 and 2) | 73 (10) | 52-93 | 72 (20) 31-113 | 0.031* | 73 (10) | 52-93 | 72 (20) 31-113 | 0.028* |
DEF6-negative /p53 (scores 0 and 3) | 64 (17) | 30–99 | 76 (79) 0–230 | 64 (17) | 30–97 | 76 (79) 0–230 | ||
DEF6-postive /p53 (scores 1 and 2) | 48 (11) | 26–70 | 48 (25) 0–97 | 44 (10) | 22–65 | 31 (16) 0–62 | ||
DEF6-positive /p53 (scores 0 and 3) | 29 (6) | 16–41 | 19 (2) 13–24 | 28 (6) | 16–41 | 17 (1) 14–19 |